Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EBITDA (2021 - 2025)

Historic EBITDA for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.7 million.

  • SAB Biotherapeutics' EBITDA fell 1211.03% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 1657.83%. This contributed to the annual value of -$42.9 million for FY2024, which is 1269.9% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' EBITDA is -$12.7 million, which was down 1211.03% from -$9.7 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' EBITDA registered a high of $813924.0 during Q1 2021, and its lowest value of -$18.9 million during Q4 2023.
  • In the last 5 years, SAB Biotherapeutics' EBITDA had a median value of -$7.8 million in 2022 and averaged -$8.2 million.
  • In the last 5 years, SAB Biotherapeutics' EBITDA crashed by 92407.44% in 2022 and then skyrocketed by 4696.96% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' EBITDA stood at -$7.3 million in 2021, then decreased by 7.02% to -$7.9 million in 2022, then tumbled by 140.12% to -$18.9 million in 2023, then surged by 46.97% to -$10.0 million in 2024, then fell by 26.68% to -$12.7 million in 2025.
  • Its EBITDA was -$12.7 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$10.8 million in Q1 2025.